| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| A012301 | The purpose of this study is to compare low-dose tamoxifen versus standard-of-care endocrine therapy for 5 years to see if the recurrence-free interval is equivalent between groups, among post-menopausal women with early stage, low risk breast cancer. Follow-up continues for up to 10 years. | Cancer | Breast |
| A032201 | This study compares the addition of tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). | Cancer | Renal |
| A092205 | This study compares the efficacy of cetuximab and pembrolizumab versus pembrolizumab alone in the treatment of recurrent and/or metatstatic head and neck squamous cell carcinoma. | Cancer | Head & Neck |
| EA5162 | This study aims to evaluate the safety and efficacy of osimertinib (AZD9291) among patients with non-small cell lung cancer with EGFR exon 20 insertions. | Cancer | Lung |
| EA5231 | This study compares adding AZD6738 to durvalumab versus durvalumab alone, following treatment with chemotherapy and surgery, in the treatment of patients with non-small cell lung cancer. | Cancer | Non-Small Cell Lung |
| NRG-GI011 | This study evaluates the overall survival rate of advanced pancreatic cancer patients who pursue dose-escalated radiation therapy versus standard treatment without dose-escalated radiation therapy at 3 years. | Cancer | Pancreatic |
| S1800E (LUNGMAP substudy) | This study is comparing a regimen of Docetaxel and Ramucirumab with or without Cemiplimab for participants with recurrent Non-Small Cell Lung Cancer, previously treated with platinum-basesd chemotherapy and immunotherapy. | Cancer | Non-Small Cell Lung |
| S1931 | This study evaluates adding surgery (radical or partial nephrectomy) to standard immunotherapy-based drug treatments for patients with metastatic renal cancer. | Cancer | Metastatic Renal |
| S2414 | This study compares disease free survival rate in patients treated with durvalumab after surgery versus observation only with early-stage non-small cell lung cancer. | Cancer | Non-Small Cell Lung |
| A071701 | This study is for patients who brain metastasis. Patients must have an actionable alteration in NTRK, ROS1, KRAS G12C or CDK pathway or P13K. | Cancer | Brain Mets |
| A072201 | This study if for patients with recurrent glioblastomas. It is looking at standard of care treatment (Lomustine) vs Anti-LAG-3 and Anti-PD-L1 Blockade. | Cancer | Glioblastoma |
| NRG GU013 | This study is for patients with high risk prostate cancer. PSA must be >20 ng/ml. Patient must have a Gleason score of 8-10. Patient cannot have metastatic disease outside of pelvic lymph nodes. No prior radiation or androgen deprivation therapy allowed. | Cancer | Prostate |
| NRG-GU011 | The purpose of this study is to look at adding Androgen deprivation therapy in patients with prostate cancer with only a few areas of metastasis. You must have had prior curative intent treatment to the prostate. | Cancer | Prostate |
| RTOG 1216 | This study is for patients with squamous cell cancer of the head and neck. It looks at after surgery adding radiation to the standard of care chemotherapy to treat the cancer. | Cancer | Head & Neck |
| S1900G (LUNGMAP substudy) | The purpose of this study is to determine if adding ramucirumab in combination with capmatinib and osimertinib is effective in treating patients with Stage 4 or recurrent non-small cell lung cancer. | Cancer | Metastatic Non-Small Cell Lung |
| S1900J (LUNGMAP substudy) | The purpose of this study is see if Amivanatamab is effective in treating patients with MET-Amplification Positive Stage 4 or recurrent non-small cell lung cancer. | Cancer | Metastatic Non-Small Cell Lung |
| S1900K (LUNGMAP substudy) | The purpose of this study is to determine if the use of Tepotinib with or without Ramucirumab is effective in patients with MET Exon 14 skipping positive stage 4 or recurrent non-small cell lung cancer (NSCLC).(LUNGMAP sub-study) | Cancer | Metastatic Non-Small Cell Lung |
| S2312 | This study is for patients with metastatic prostate cancer. It looks at using Cabazitaxel with or without carboplatin in patients with castrate-resistant prostate cancer. | Cancer | Prostate |
| S2303 | This study is for patients who have progressed on standard of care treatment for gastric or esophageal cancer. The study looks at adding Nivolumab to 2nd line treatment to see if it improves outcomes. | Cancer | Gastric or Esophageal |
| EA5221 | The purpose of this study is to determine in the older adult population if immunotherapy alone is better than immunotherapy + chemotherapy. Patients must be 70+ with diagnosis of Non-Small Cell Lung Cancer. | Cancer | Non-Small Cell Lung Cancer |
| NRG BN011 | The purpose of this study is to determined if combination therapy radiation is more effective than single agent therapy with radiation. Patients must be diagnosed with a Methylated MGMT promoter Gliblastoma. | Cancer | Gliblastoma |
| NRG CC011 | This study is for patients with stage 1-3 breast cancer. Patient must be > 6 months to 5 years out from treatment and experiencing symptoms of brain fog. The study using cognitive training to try to improve brain fog symptoms. | Cancer | Breast |
| A032103 | The purpose of this study is to use central DNA testing to monitor recurrance in patients with urothelial cancer. You must have had a radical cysectomy and lymph node dissection with no evidence of residual cancer. | Cancer | Urothelial |
| EAY191-N5 | This study is for patient's who have HER2+ gynecologic cancers or other solid tumors. Cannot have breast cancer. You must have recurrent disease or progressed on treatment. | Cancer | Her2+ Solid Tumors |
| S2101 | This study is for patients with Stage III or IV, unresectable, recurrent, or metastatic melanoma. This study uses Nivolumab and Cabozantinib to treat patients. | Cancer | Melanoma |
| S2013 | The purpose of this study is the look at the side effects of immunotherapy treatment. You must be starting immunotherapy alone not in combination with other treatments. You must have a solid tumor. | Cancer | Solid Tumors |
| NRG-BR009 | The purpose of this study is treat breast cancer after surgery. You must have estrogen positive breast cancer and an oncotype score ≤25. This study looks at adding chemotherapy to the standard treatment of ovarian function suppression and aromatase inhibitor. | Cancer | Breast |
| GU012 | The purpose of this study is to compare standard immunotherapy with immunotherapy and radiation. You must be diagnosed with metastatic renal cell cancer and have not had surgery for this cancer. | Cancer | Metastatic Renal Cell |
| S2209 | This study is for frail-intermediately fit newly diagnosed multiple myeloma patients. Your current lab values will be used to determine if you qualify for this study. This study compares different chemo regimens to determine the effectiveness of them. | Cancer | Multiple Myeloma |
| A031701 | The purpose of this study is to compare standard or dose dense gemcitabine and cisplatin chemo. You must have been diagnosed with muscle invasive bladder cancer. | Cancer | Bladder |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.